Multicomponent Intervention for Physical Frailty and Sarcopenia (SPRINTT)

February 1, 2017 updated by: Roberto Bernabei, Catholic University of the Sacred Heart

Sarcopenia and Physical fRailty IN Older People: Multi-componenT Treatment Strategies (SPRINTT)

The SPRINTT study will evaluate the efficacy of a multicomponent intervention programme (physical activity, nutritional counselling/dietary intervention, and information and communications technology intervention) compared with a healthy aging lifestyle education programme on mobility disability, in non-disabled older people with physical frailty and sarcopenia.

Study Overview

Detailed Description

As the life expectancy in European countries continues to increase, the maintenance of physical independence in older persons has become a major public health priority. The ability to ambulate without assistance is crucial for independent living and it is often the first ability to be lost in the process leading to disability. Older people who have impaired walking function need more assistance and are more likely to be placed in nursing homes, have a higher risk of morbidity, mortality and hospitalisation, and experience a reduced quality of life. The ultimate goals of the Sarcopenia and Physical fRailty IN older people: multicomponenT Treatment strategies (SPRINTT) project are to offer efficient treatment options, based on a multicomponent intervention including physical activity, nutrition and information and communications technology, to physically frail, sarcopenic older persons and to improve their quality of life. The result will directly contribute to the long-term sustainability and efficiency of health- and social-care systems. The conceptualisation of physical frailty and sarcopenia (PF&S) as proposed in SPRINTT will promote significant advancements over the traditional approaches by enabling the precise operationalisation of the condition, a clear identification of the affected population and the rapid translation of findings to the clinical arena.

Study Type

Interventional

Enrollment (Anticipated)

1500

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Rome, Italy, 00168
        • Recruiting
        • Catholic University of the Sacred Heart
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

66 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria:

  1. Short Physical Performance Battery (SPPB) score between 3 (included) and 9 (included);
  2. Able to complete the 400-m walk test within 15 min without sitting down, help from another person, use of a walker, or stopping for more than 1 minute at a time;
  3. Presence of low muscle mass based on Dual Energy X-Ray Absorptiometry (DXA) scan, according to the Foundation for the National Institutes of Health Sarcopenia Project (FNIH) criteria:

    • Body mass index-adjusted appendicular lean mass (aLM; i.e., the sum of lean mass from both arms and legs): <0.789 in men, and <0.512 in women OR
    • aLM <19.75 kg in men and <15.02 kg in women
  4. Willingness to be randomised to either intervention group and to follow the study protocol.

Exclusion criteria:

General

  1. Unable or unwilling to provide informed consent or accept randomisation to either study group.
  2. Plans to relocate out of the study area within the next 2 years or plans to be out of the study area for more than 6 consecutive weeks in the next year;
  3. Residence in long-term care;
  4. Household member enrolled in the study.

Clinical conditions:

  1. Current diagnosis of schizophrenia, other psychotic or bipolar disorder;
  2. Consumption of more than 14 alcoholic drinks per week;
  3. Difficulty communicating with the study personnel due to speech, language, or (non-corrected) hearing problems;
  4. Mini Mental State Examination lower than 24/30;
  5. Severe osteoarthritis (e.g., awaiting joint replacement) that would interfere with the ability to participate fully in either study arm;
  6. Cancer requiring treatment in the past 3 years, except for non-melanoma skin cancers or cancers that have an excellent prognosis (e.g., early stage breast or prostate cancer);
  7. Lung disease requiring regular use of supplemental oxygen;
  8. Inflammatory conditions requiring regular use of oral or parenteral corticosteroid agents;
  9. Severe cardiovascular disease (including New York Heart Association class III or IV congestive heart failure, clinically significant valvular disease, history of cardiac arrest, presence of an implantable defibrillator, or uncontrolled angina)
  10. Upper and/or lower extremity amputation;
  11. Peripheral arterial disease Lériche-Fontaine 3 or 4;
  12. Parkinson's disease or other progressive neurological disorder;
  13. Renal disease requiring dialysis;
  14. Chest pain, severe shortness of breath, or occurrence of other safety concerns during the baseline 400-metre walk test;
  15. Current participation in a structured exercise programme, physical therapy or cardiopulmonary rehabilitation;
  16. Current enrolment in another randomised clinical trial involving lifestyle, nutrition, or pharmaceutical interventions;
  17. Other medical, psychiatric, or behavioural factors that in the judgment of the principal investigator may interfere with the study participation or the ability to autonomously follow either the multicomponent or the healthy aging lifestyle education programmes;
  18. Other illness of such severity that life expectancy is expected to be less than 12 months;
  19. Clinical judgment concerning safety or non-compliance.

Temporary exclusion criteria

  1. Uncontrolled hypertension (systolic blood pressure >200 mm Hg, or diastolic blood pressure >110 mm Hg);
  2. Uncontrolled diabetes with recent weight loss, diabetic coma, or frequent hypoglycaemia;
  3. Hip fracture, hip or knee replacement, or spinal surgery in the past 6 months
  4. Serious cardiac conduction disorder (e.g., third-degree heart block), uncontrolled arrhythmia, new Q waves within the past 6 months or ST-segment depression (>3 mm) on the electrocardiogram;
  5. Myocardial infarction, major heart surgery (i.e., valve replacement or coronary bypass graft), stroke, deep vein thrombosis, or pulmonary embolism in the past 6 months;
  6. Use of growth hormone, oestrogens, progesterone, or testosterone supplementation in the past 3 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Multicomponent intervention (MCI)
The multicomponent intervention will include a physical activity programme, a nutritional intervention and an information and communications intervention.

The multicomponent intervention will include physical activity (PA), nutrition and information and communications technology (ICT). The PA will be of moderate intensity and will include aerobic, strength, flexibility, and balance training. Walking will be the primary mode of PA .

The nutritional intervention will combine individual nutritional assessment and personalised dietary recommendations to achieve:

  • a daily total energy intake of 25-30 kcal/kg body weight;
  • an average protein daily intake between 1.0 and 1.2 g/Kg/body weight.

The ICT component will involve the use of an ad hoc technological device to record actimetry data to support the elaboration of a personalised training programme.

Active Comparator: Healthy Aging Lifestyle Education (HALE)
The health aging lifestyle education programme will be based on workshops. Participants will receive information on a variety of topics of relevance to older persons (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
The healthy aging lifestyle education programme will be based on a workshop series. Participants will receive information on a variety of topics of relevance to older adults (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incident of major mobility disability
Time Frame: 36 months
Incident inability to complete the 400-metre walk test (incidence of major mobility disability)
36 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in lower extremity physical performance
Time Frame: 36 months
Changes in short physical performance battery (SPPB) summary score
36 months
Changes in upper extremity muscle strength
Time Frame: 36 months
Changes in handgrip strength test performance (kg)
36 months
Changes in functional status (activities of daily living)
Time Frame: 36 months
Changes in Activities of Daily Living (ADL) score computed through a modified version of the Pepper Assessment Tool for Disability (PAT-D)
36 months
Changes in functional status (instrumental activities of daily living)
Time Frame: 36 months
Changes in Instrumental Activities of Daily Living (IADL) score computed through a modified version of the Pepper Assessment Tool for Disability (PAT-D)
36 months
Changes in crude appendicular lean mass
Time Frame: 36 months
Changes in crude in appendicular lean mass (kg) by Dual Energy X-Ray Absorptiometry
36 months
Changes in body mass index-adjusted appendicular lean mass
Time Frame: 36 months
Changes in body mass index-adjusted appendicular lean mass (adimensional) by Dual Energy X-Ray Absorptiometry
36 months
Persistent mobility disability
Time Frame: 36 months
Inability to complete the 400-metre walk test at two consecutive semiannual visits
36 months
Changes in body weight
Time Frame: 36 months
Changes in body weight (kg)
36 months
Changes in body mass index
Time Frame: 36 months
Changes in body mass index (kg/m^2)
36 months
Changes in mid-arm circumference
Time Frame: 36 months
Changes in mid-arm circumference (cm)
36 months
Changes in waist circumference
Time Frame: 36 months
Changes in waist circumference (cm)
36 months
Changes in hip circumference
Time Frame: 36 months
Changes in hip circumference (cm)
36 months
Changes in calf circumference
Time Frame: 36 months
Changes in calf circumference (cm)
36 months
Changes in nutritional status
Time Frame: 36 months
Changes in Mini Nutritional Assessment-Short Form (MNA-SF) score
36 months
Changes in cognitive function
Time Frame: 36 months
Changes in Mini Mental State Examination (MMSE) score
36 months
Changes in mood
Time Frame: 36 months
Changes in 11-item Center for Epidemiological Studies - Depression (CES-D) scale score
36 months
Incidence of self-reported falls
Time Frame: 36 months
Number of falls assessed by questionnaires
36 months
Incidence of injurious falls
Time Frame: 36 months
Number of injurious falls assessed by questionnaires
36 months
Changes in quality of life
Time Frame: 36 months
Changes in EuroQoL-5D (EQ5D) score
36 months
Changes in the use of healthcare services
Time Frame: 36 months
Health economics questionnaire
36 months
All-cause mortality
Time Frame: 36 months
Mortality rate
36 months
Cost effectiveness
Time Frame: 36 months
Cost effectiveness analysis
36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Francesco Landi, MD, PhD, Catholic University of the Sacred Heart

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2016

Primary Completion (Anticipated)

December 1, 2018

Study Completion (Anticipated)

December 1, 2018

Study Registration Dates

First Submitted

October 8, 2015

First Submitted That Met QC Criteria

October 19, 2015

First Posted (Estimate)

October 21, 2015

Study Record Updates

Last Update Posted (Estimate)

February 2, 2017

Last Update Submitted That Met QC Criteria

February 1, 2017

Last Verified

February 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sarcopenia

Clinical Trials on Multicomponent intervention (MCI)

Subscribe